C-S5SWHOX biologics, degradation resistance, transcription factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a tandem CAR-T and hematopoietic stem cell transplantation platform for hematologic malignancies.
Cell-therapy and HSC transplantation platform supported by NCI STTR Phase I preclinical development funding.
NCI STTR Phase I Notice of Award received on 2025-09-09 for preclinical development.
Speed recovery from neutropenia secondary to chemotherapy and stem cell transplant by expanding stem cells in vivo.
HOX-family stem-cell expansion stimulant; related patent covers compositions and methods for expansion of stem cells using HOXB4 or mutant HOX proteins.
NHLBI SBIR Phase II grant awarded on 2025-08-21 for stimulant-driven in vivo stem cell expansion after earlier Phase I support in 2021.
Create HOX-family transcription-factor biologics that resist intracellular degradation and can be used as pharmaceuticals without frequent repeat dosing.
Modify conserved domains of homeobox transcription factors to produce degradation-resistant, nuclear-targeting biologics.
NHLBI Catalyze R33 grant awarded in 2022 and extended in 2023 for preclinical development of a nuclear-targeting biologic.
Accelerate closure of chronic wounds in diabetic and aged populations.
Topical HOXA3-based intervention; published evidence used HoxA3 plasmid delivered topically in a hydrogel, while company materials describe degradation-resistant HOX-family biologics as the pharmaceutical direction.
Lead product reported as set to enter clinical trials by 2025; NIA SBIR Phase I grant awarded for chronic wound healing in aging populations and 2023 preclinical wound-healing results published.
In mice, topical HoxA3 produced faster healing in diabetic wounds and complete closure of aged non-diabetic wounds by two weeks, while untreated wounds were about 50% closed.